Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
38 hedge funds and large institutions have $4.53M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 14 closing their positions.
61% more capital invested
Capital invested by funds: $2.81M → $4.53M (+$1.72M)
1.5% less ownership
Funds ownership: 15.82% → 14.32% (-1.5%)
24% less funds holding
Funds holding: 50 → 38 (-12)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$147K |
| 2 |
PPW
Pasadena Private Wealth
Pasadena,
California
|
+$79.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$13.5K |
| 5 |
IIA
IPG Investment Advisors
San Diego,
California
|
+$8.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$144K |
| 2 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
-$138K |
| 3 |
BJL
Brighton Jones LLC
Seattle,
Washington
|
-$102K |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$27.5K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$16.2K |
ONCT Hedge Fund Activity: Q4 2023 in Review
38 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2023, worth a combined $4.53M — up 61% from $2.81M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ONCT and 3 opened new positions — a net loss of 11 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, adding an estimated $147K. The largest seller was Geode Capital Management, exiting entirely with an estimated $144K sold.
- 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2023, down from 50 in Q3 2023.
- Funds reported $4.53M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2023, up 61% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2023 and 14 closed out, a net change of -11 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2023 was Millennium Management, an estimated $147K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2023 was Geode Capital Management, an estimated $144K sold.
Based on aggregated 13F filings for Q4 2023.